Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

Fig. 2

Amyloid-β plaque reduction with gantenerumab. Axial florbetapir brain PET images from five patients displaying reduction of amyloid-β plaques from OLE baseline to OLE week 52 and OLE week 104. Axial slices are at the level of the basal ganglia. PET images were obtained 50 min post-injection, SUVR data with the cerebellar cortex as the reference region

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193